MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1210/clinem/dgab428

Медицинская библиотека · The Journal of clinical endocrinology and metabolism · 2021

Glucose-lowering Drugs and Hospitalization for Heart Failure: A Systematic Review and Additive-effects Network Meta-analysis With More Than 500 000 Patient-years.

Cintra Riobaldo M, Nogueira Ana Claudia, Bonilha Isabella, Luchiari Beatriz M, Coelho-Filho Otavio R, Coelho Otavio R, Schwartzmann Pedro, Muscellie Elza, Nadruz Wilson, Carvalho Luiz Sergio F, Sposito Andrei C

СтатьяПоддержка исследования: вне правительства СШАСистематический обзорNetwork Meta-AnalysisПеревод пока не подготовлен

Аннотация

BACKGROUND

Sodium glucose co-transporter 2 inhibitors (SGLT2is) prevent hospitalization resulting from heart failure (HHF). However, patients with type 2 diabetes mellitus use multiple antihyperglycemic drugs to achieve glycosylated hemoglobin (HbA1c) targets. In these drug combinations, the risk of HHF is unpredictable and so is the parallel effect of glucose-lowering.

PURPOSE: To examine the impact of antihyperglycemic drugs and their association on HHF.

DATA SOURCES: Forty randomized controlled trials (RCTs) reporting HHF.

STUDY SELECTION: Published RCTs were the data source.

DATA EXTRACTION: Incidence rates of HHF.

DATA SYNTHESIS: Random additive-effects network meta-analysis showed that metformin (P = 0.55), sulfonylureas (P = 0.51), glucagon-like peptide-1 receptor-agonist (P = 0.16), and dipeptidyl peptidase 4 inhibitors (DPP4is; P = 0.54) were neutral on the risk of HHF. SGLT2is and SGLT2is + DPP4is reduced the risk of HHF with a hazard ratio (HR) of 0.68 (95% CI, 0.60-0.76; P < 0.0001) and 0.70 (95% CI, 0.60-0.81; P < 0.0001), respectively. Increased risk of HHF was associated with thiazolidinediones (TZDs) as monotherapy or in combination with DPP4is (HR: 1.45; 95% CI, 1.18-1.78; P = 0.0004) and 1.49 (95% CI, 1.18-1.88; P = 0.0008), respectively. Regardless of the therapy, a 1% reduction in HbA1c reduced the risk of HHF by 31.3% (95% CI, 9-48; P = 0.009).

LIMITATIONS: There are no data to verify drug combinations available for clinical use and to discriminate the effect of drugs within each of the therapeutic classes.

CONCLUSIONS

The risk of HHF is reduced by SGLT2is as monotherapy or in combination with DPP4is and increased by TZDs as monotherapy or in combination. Glucose-lowering provides an additive effect of reducing HHF.

Для цитирования: Cintra Riobaldo M, Nogueira Ana Claudia, Bonilha Isabella, Luchiari Beatriz M, Coelho-Filho Otavio R, Coelho Otavio R, Schwartzmann Pedro, Muscellie Elza, Nadruz Wilson, Carvalho Luiz Sergio F, Sposito Andrei C. Glucose-lowering Drugs and Hospitalization for Heart Failure: A Systematic Review and Additive-effects Network Meta-analysis With More Than 500 000 Patient-years.. The Journal of clinical endocrinology and metabolism. 2021. DOI: 10.1210/clinem/dgab428.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.